tetano
Editor, Senior Moderator
J Infect Dis
. 2024 Jan 9:jiad612.
doi: 10.1093/infdis/jiad612. Online ahead of print. Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
Caroline E Harrer[SUP] 1 2 3 [/SUP], Leonie Mayer[SUP] 1 2 3 [/SUP], Anahita Fathi[SUP] 1 2 3 4 [/SUP], Susan Lassen[SUP] 1 2 3 [/SUP], My L Ly[SUP] 1 2 3 [/SUP], Madeleine E Zinser[SUP] 1 2 3 [/SUP], Timo Wolf[SUP] 5 [/SUP], Stephan Becker[SUP] 6 7 [/SUP], Gerd Sutter[SUP] 8 9 [/SUP], Christine Dahlke[SUP] 1 2 3 [/SUP], Marylyn M Addo[SUP] 1 2 3 4 [/SUP]; MVA-MERS-S Study Group
Collaborators, Affiliations
Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The Modified Vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of three candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A*03:01/HLA-B*35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.
Keywords: CD8+ T cells; MERS-CoV; MVA; epitope; vaccine; viral vector.
. 2024 Jan 9:jiad612.
doi: 10.1093/infdis/jiad612. Online ahead of print. Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
Caroline E Harrer[SUP] 1 2 3 [/SUP], Leonie Mayer[SUP] 1 2 3 [/SUP], Anahita Fathi[SUP] 1 2 3 4 [/SUP], Susan Lassen[SUP] 1 2 3 [/SUP], My L Ly[SUP] 1 2 3 [/SUP], Madeleine E Zinser[SUP] 1 2 3 [/SUP], Timo Wolf[SUP] 5 [/SUP], Stephan Becker[SUP] 6 7 [/SUP], Gerd Sutter[SUP] 8 9 [/SUP], Christine Dahlke[SUP] 1 2 3 [/SUP], Marylyn M Addo[SUP] 1 2 3 4 [/SUP]; MVA-MERS-S Study Group
Collaborators, Affiliations
- PMID: 38195212
- DOI: 10.1093/infdis/jiad612
Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The Modified Vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of three candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A*03:01/HLA-B*35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.
Keywords: CD8+ T cells; MERS-CoV; MVA; epitope; vaccine; viral vector.